Top Page
Nova Eye Medical
(OTC:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 26.11M | 23.32M | 17.02M | 13.38M | 13.39M | 12.77M | Gross Profit |
| 19.82M | 20.19M | 842.00K | -765.00K | 1.77M | -1.64M | EBIT |
| -3.55M | -8.97M | -11.85M | -9.88M | -4.96M | -7.17M | EBITDA |
| -6.72M | -5.98M | -9.48M | -7.89M | -3.67M | -5.75M | Net Income Common Stockholders |
| -8.56M | -8.79M | -15.29M | -7.50M | -4.36M | -6.99M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.21M | 6.15M | 7.42M | 8.00M | 17.80M | 95.65M | Total Assets |
| 59.22M | 29.88M | 30.36M | 36.63M | 41.99M | 116.74M | Total Debt |
| 5.20M | 3.35M | 1.53M | 1.94M | 3.70M | 3.34M | Net Debt |
| 987.00K | -2.80M | -5.89M | -6.06M | -14.10M | -92.31M | Total Liabilities |
| 17.93M | 8.55M | 7.17M | 6.23M | 6.66M | 16.16M | Stockholders Equity |
| 41.30M | 21.33M | 23.19M | 30.40M | 35.34M | 100.59M |
| Cash Flow | Free Cash Flow | ||||
| -7.42M | -8.31M | -7.52M | -10.27M | -15.13M | 3.79M | Operating Cash Flow |
| -7.32M | -7.86M | -6.72M | -4.68M | -12.90M | 5.45M | Investing Cash Flow |
| -230.00K | -325.00K | -800.00K | -4.58M | -3.22M | 88.26M | Financing Cash Flow |
| 6.89M | 6.91M | 6.82M | -402.00K | -61.61M | -13.29M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$34.10M | ― | -50.50% | ― | 39.08% | 53.31% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
50 Neutral | AU$51.90M | ― | -8.08% | ― | -5.62% | -225.71% | |
48 Neutral | AU$151.79M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$118.92M | ― | -35.20% | ― | 4.68% | -155.42% | |
41 Neutral | AU$34.03M | ― | -135.33% | ― | -27.58% | 33.69% | |
41 Neutral | AU$10.31M | ― | -98.08% | ― | -7.44% | 30.34% |
Nova Eye Medical Corporate Events
Nova Eye Medical Limited has announced the application for quotation of 21,000 ordinary fully paid securities on the Australian Securities Exchange, issued under an employee incentive scheme. This move reflects the company’s ongoing efforts to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement.
Nova Eye Medical Limited has announced an investor webinar, highlighting its commitment to delivering on promises by selling highly effective ophthalmic products that are in demand among eye surgeons. This announcement underscores the company’s strategic focus on capitalizing on a growing market, which could enhance its industry positioning and potentially benefit stakeholders.
Nova Eye Medical Ltd has issued 45,236 shares to an American consultant as part of a consulting agreement. This move, executed without the need for disclosure under the Corporations Act, signifies the company’s compliance with regulatory requirements and may enhance its operational capabilities and market positioning.
Nova Eye Medical Limited has announced the quotation of 45,236 ordinary fully paid securities on the ASX, effective May 6, 2025. This move is part of a consulting agreement in America aimed at enhancing clinical marketing, new product development, peer-to-peer education, and clinical investigations, which could strengthen the company’s market position and stakeholder engagement.
Nova Eye Medical has announced an upcoming Investor Webinar on 6 May 2025, where Managing Director Tom Spurling will discuss the company’s March 2025 Quarterly Activities and Cashflow Report. The report highlights record US sales, revenue growth, and improved profitability in glaucoma treatments. Additionally, Nova Eye Medical is exploring opportunities to expand its iTrack™ technology into ocular drug delivery markets, indicating potential future growth and innovation in their product offerings.
Nova Eye Medical Limited reported strong financial performance for the March 2025 quarter, with a 27% increase in sales compared to the previous corresponding period, excluding China. The company achieved record sales in the USA, contributing to a significant reduction in losses within the glaucoma segment. The company also identified potential growth opportunities in ocular drug delivery using its proprietary iTrack™ technology, further strengthening its market position.
Nova Eye Medical Limited announced the issuance of 7,000 ordinary fully paid securities to be quoted on the Australian Securities Exchange (ASX) as of March 28, 2025. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities, potentially benefiting stakeholders by aligning employee interests with company performance.
Nova Eye Medical Limited has announced a change in the director’s interest, specifically concerning Victor Previn. The change involves an indirect interest through Sedico Pty Ltd as trustee, with an acquisition of 416,666 ordinary securities valued at $49,999.92, approved at a general meeting on 19 March 2025. This adjustment in director’s interest reflects the company’s ongoing governance and compliance with ASX listing rules.
Nova Eye Medical Limited has announced the quotation of 20,833,334 fully paid ordinary shares on the Australian Securities Exchange (ASX) under the code EYE. This move is part of a previously announced transaction and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the availability of its shares for trading.
Nova Eye Medical Ltd has announced the issuance of 20,833,334 new fully paid ordinary shares to professional and institutional investors, raising approximately $6.6 million. This move, which includes shares allocated to directors, follows shareholder approval and aims to strengthen the company’s financial position.
Nova Eye Medical Limited held a General Meeting on March 19, 2025, where several resolutions were passed. These resolutions included the approval of additional placement shares and the participation of directors in the placement, as well as the ratification of the placement performed. The results indicate strong support for the resolutions, with each receiving over 84% approval, reflecting confidence in the company’s strategic direction and potential positive implications for its stakeholders.